| BDX |
Report |
Adjusted EPS (FQ3'26, continuing ops) |
BEAT |
pred ~$3.22 vs. cons $3.14 |
MEDIUM |
| BDX |
Report |
FX-neutral organic revenue growth |
IN-LINE |
pred ~2.7% vs. cons ~2.6% |
MEDIUM |
| BDX |
Report |
Adjusted operating margin |
IN-LINE |
pred ~24.4% vs. cons ~24.6% |
LOW |
| BDX |
Guide |
FY26 adjusted EPS guide |
UNCHANGED |
guide ~$12.52-$12.72 vs. cons ~$12.62 (FY26) |
MEDIUM |
| BDX |
Guide |
FY26 FX-neutral revenue growth guide |
UNCHANGED |
guide ~mid-single-digit (~3%) vs. cons ~2.6% (FY26) |
MEDIUM |
| BDX |
Guide |
Implied FQ4 EPS (from held FY guide) |
LOWER |
implied ~$4.00-$4.20 vs. cons ~$4.10 (FQ4) — back-half loaded, high bar |
MEDIUM |
| BDX |
Guide |
Initial FY27 framing (Alaris 200bps headwind, tariff/resin) |
UNKNOWN |
qualitative cautious vs. cons ~+5% EPS growth (FY27) |
LOW |
| BDX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.5% |
— |
MEDIUM |
| BDX |
Return |
5-day cumulative residual |
-5.5% (FOLLOW-THROUGH) |
Stock rallied ~+11.6% into the print (from ~$153 to $170.69), so the bar is high and expectations are elevated. Even a modest EPS beat is likely 'sold the news' given the run-up. Crucially, the out-period math is unfavorable: holding the $12.52-$12.72 FY guide off a ~$3.14-$3.22 Q3 implies a very aggressive ~$4.00-$4.20 Q4, and only ~2.6-2.7% FX-neutral growth underneath. As the Street reconciles the back-half-loaded implied Q4 and a cautious early FY27 setup (Alaris headwind stepping to ~200bps, tariff/resin inflation, hedges rolling off), estimates drift lower, driving continued negative follow-through over the week rather than a rebound. |
LOW |